Table 2.
Description of strains and antigens used in the papers visited for this review.
| Reference | Model | Strain | Antigen | Challenge | Protectiona |
|---|---|---|---|---|---|
| (31) | Mice | BCG Tokyo | rBCG1:Ag85B–CFP10(rBCG1)/BCG2:Ag85B–CFP10–IL-12 (rBCG2) | No | > (Ex vivo) |
| (49) | Human | BCG Tice | rBCG30 (Ag 85B) | No | NE |
| (46) | Guinea pigs | BCG Danish | rBCG–E6 (ESAT-6) | 50–100 bacilli of Mtb | > |
| (41, 42) | Guinea pigs | BCG Danish | rBCGacr | 50–100 bacilli of Mtb | > |
| (39) | Mice | BCG Danish | BCG:HspX/rBCG:85B | 106 CFU of Mtb | > |
| (53) | Mice | BCG China | rBCG–AE | 106 CFU of Mtb | < |
| (58) | Mice | BCG Prague | rBCGureC:hly or rBCGureC:hly | 102 CFU of Mtb | = |
| (45) | Mice | BCG Danish | BCG: rBCG–Ag85B–Mpt64–Mtb8.4 | 106 CFU of Mtb | > |
| (47) | Mice | BCG Danish | rBCG:Ag85B–ESAT-6–Rv2608 | No | NE |
| (33) | Monkey | BCG Tokyo | rBCG–Ag85A | 3000 CFU of Mtb | > |
| (48) | Monkey | BCG Danish | rBCG AFRO-1 | No | NE |
| (55) | In vitro | BCG China | rBCG:Quimera 85B + ESAT-6 | No | NE |
| (34) | Mice | BCG Pasteur | rBCG:PE–MPT64/rBCG/HSP60MPT64 | ~200 CFU of Mtb | > |
| (23) | Mice | BCG Prague | rBCGΔureC:hly+ | 200–400 CFU of Mtb | > |
| (51) | Mice | BCG China | rBCG: Ag85A/rBCG:Ag85B/rBCG:Ag85A–Ag85B | 106 CFU of Mtb | > |
| (52) | Mice | BCG China | rBCG: Ag85A–ESAT-6/rBCG: Ag85A/rBCG: ESAT-6 | No | NE |
| (40) | Monkey | BCGDanish | AFRO-1, Ag85A, Ag85B e TB10.4. | 500 CFU of Mtb | > |
| (37) | Mice | BCG Pasteur | rBCGs:BCG:Ag85c, BCG:INV, BCG:PPE, BCG:FBP e BCG:CFP | 20 bacilli of Mtb | = |
| (57) | Mice | BCG Prague | rBCGΔureC:hly+) | No | NE |
| (38) | Mice | BCG Pasteur | rBCG: pHspX–Ag 85B | 100 bacilli of Mtb/lung | = |
| (56) | Mice | BCG China | rBCGs:BCG:GM-CSF/BCG:ESAT-6/BCG:GMCSF–ESAT-6 | No | NE |
| (32) | Mice | BCG Tokyo | rBCG–85B–IL-15/rBCG–85B | 2 × 105 CFU of Mtb | = |
| (44) | Guinea pigs | BCG Danish | rBCG–85C | 500 bacilli of Mtb | > |
| (59) | Human | BCG Danish | BCG ΔureC:hly HmR | No | NE |
aProtection was evaluated by CFU analyses and considered when the bacterial load of challenged animals were lower than wild type BCG-vaccinated animals; >, superior than BCG; =, protection similar to BCG; –, less protection than BCG; NE, not evaluated.
References published and indexed in PubMed from 2008 to April 2013.